Aurobindo Pharma's CuraTeQ approved to market Bevqolva for colorectal cancer
NewsBytes | May 16, 2026 4:39 PM CST
Aurobindo shares steady after USFDA inspection
Meanwhile, Aurobindo's Telangana facility wrapped up a US Food and Drug Administration inspection with only minor issues and no extra regulatory hurdles.
After these updates, the company's shares stayed steady at ₹1,510.3, up 8.9% in the past month and over 26% so far this year.
Not bad for one of India's big names in pharma!
READ NEXT
-
Mateus Mane’s Rise: From Bench to Breakthrough at Wolves Amid Interest from Manchester United and Liverpool
-
Rising to Greatness: How Barcelona’s Sydney Schertenleib Became Women’s Football’s Brightest Young Star
-
Chelsea’s WSL Reign Unravels: How Sonia Bompastor’s Risky Approach Backfired and What Lies Ahead for the Blues
-
Lionel Messi reacts to Inter Miami fans’ protest over players’ ‘respect’ concerns during MLS victory against Portland Timbers
-
Mario Basler: The Bayern Munich Maverick Whose Talent and Rebellious Spirit Defined an Era
